{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Chi-squared","testedNonInferiority":false},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"46"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"253"},{"groupId":"OG002","value":"257"}],"units":"Participants"}],"description":"Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12.","groups":[{"description":"Placebo subcutaneous injection (given under the skin by way of a needle) matched to golimumab administered at Week 0 and Week 2.","id":"OG000","title":"Placebo"},{"description":"Golimumab 200 mg subcutaneous injection was administered at Week 0 and dose was decreased to 100 mg at Week 2.","id":"OG001","title":"Golimumab 200 mg -> 100 mg"},{"description":"Golimumab 400 mg subcutaneous injection was administered at Week 0 and dose was decreased to 200 mg at Week 2.","id":"OG002","title":"Golimumab 400 mg -> 200 mg"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis population included all the participants who were randomly assigned to the study after the dose selection.","reportingStatus":"POSTED","timeFrame":"Week 6","title":"Number of Participants With Clinical Remission at Week 6","type":"SECONDARY","unitOfMeasure":"Participants"}